News Releases:

2016

miRagen Therapeutics Expands Executive Leadership Team

BOULDER, CO – November 29, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need, today announced the appointment of Paul Rubin,... View »

miRagen Therapeutics Announces Presentation of MRG-106 Clinical Data at American Society of Hematology Annual Meeting

BOULDER, CO – November 3, 2016 – miRagen Therapeutics, Inc. today announced that data from its ongoing Phase 1 clinical study of MRG-106 in patients with mycosis fungoides will be presented at the 58th Annual Meeting of the American Society... View »

miRagen Therapeutics and Signal Genetics Sign Merger Agreement

BOULDER, CO & CARLSBAD, CA.- October 31, 2016 – (BUSINESS WIRE)- Signal Genetics, Inc. (Nasdaq: SGNL) (“Signal”) and Miragen Therapeutics, Inc. (“miRagen”), a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which... View »

miRagen Therapeutics to Present at the 2016 Wedbush PacGro Healthcare Conference

BOULDER, CO – August 11, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, today announced its participation in the 2016 Wedbush PacGrow Healthcare Conference. Conference Details: The 2016 Wedbush PacGrow Healthcare Converence On August... View »

miRagen Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016

BOULDER, CO – July 6, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, today announced its participation in the Cantor Fitzgerald 2nd Annual Healthcare Conference. Conference Details: The Cantor Fitzgerald 2nd Annual Healthcare Conference On... View »

miRagen and The ALS Association announce grant for ALS product candidate MRG-107, a synthetic microRNA antagonist (LNA antimiR®) of microRNA-155

BOULDER, CO and WASHINGTON, D.C. – June 2, 2016 – Today, miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, and The ALS Association announced that miRagen has received the first installment of a Translational Research Advancing Therapy for... View »

miRagen announces expansion of senior management team, appointing Adam Levy as CBO

BOULDER, Colorado, – June 2, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, today announced the appointment of Adam Levy to the position of Chief Business Officer. Concurrent with Mr. Levy’s appointment, Christopher J. Morl has... View »

miRagen Therapeutics Initiates First Clinical Trial for MRG-106 in Lymphoma Patients

BOULDER, Colorado, – March 2, 2016 – miRagen Therapeutics, Inc. a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, today announced that it has initiated a Phase 1 clinical study of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR®)... View »